The Vanguard Group, Inc. recently announced the acquisition of new stake in Artivion Inc. (NYSE:AORT). The institutional investor has increased its shareholding in the Healthcare company by 1.52% to 2.66 million shares with purchase of 39825.0 shares. This fresh investment now brings its stake to 6.59% valued currently at $32.19 million. In addition, Macquarie Investment Management B raised its holdings by 0.19 million to 2.59 million shares. And Juniper Investment Co. LLC has lifted its position by 8.01% or 0.15 million shares – to 2.09 million shares.
With over 0.12 million Artivion Inc. (AORT) shares trading Monday and a closing price of $12.92 on the day, the dollar volume was approximately $1.51 million. The shares have shown a negative half year performance of -34.62% and its price on 01/23/23 gained nearly 1.73%. Currently, there are 40.12M common shares owned by the public and among those 37.23M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for AORT have a consensus price objective of $23.13. The analysts have set the share’s price value over the next 12 months at a high of $30.75 and a low of $14.00. The average price target is 44.12% above its recent price level and an upside to the estimated low will see the stock gain 7.71% over that period. But an upside of 57.98% will see the stock hit the forecast high price target while median target price for the stock is $24.00.
Insiders at the company have transacted a total of 112 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 53 of these insider trades were purchases, accounting for 645,805 shares. Insider sales of the common stock occurred on 59 occasions, with total insider shares sold totaling 121,410 shares.
The top 3 mutual fund holders in Artivion Inc. are iShares Core S&P Small Cap ETF, Delaware Small Cap Core Fund, and Wasatch Ultra Growth Fund. iShares Core S&P Small Cap ETF owns 3.01 million shares of the company’s stock, all valued at over $36.45 million. The company sold 2288.0 shares recently to bring their total holdings to about 7.46% of the shares outstanding. Delaware Small Cap Core Fund bought 15740.0 shares to see its total holdings expand to 1.99 million shares valued at over $24.15 million and representing 4.94% of the shares outstanding. Wasatch Ultra Growth Fund sold -0.34 million shares to bring its total holdings to over 1.66 million shares at a value of $20.07 million. Wasatch Ultra Growth Fund now owns shares totaling to 4.11% of the shares outstanding.
Shares of Artivion Inc. (NYSE: AORT) opened at $12.65, down -$0.05 from a prior closing price of $12.70. However, the script later moved the day high at 13.00, up 1.73%. The company’s stock has a 5-day price change of 1.10% and 24.95% over the past three months. AORT shares are trading 6.60% year to date (YTD), with the 12-month market performance down to -26.72% lower. It has a 12-month low price of $9.64 and touched a high of $23.43 over the same period. AORT has an average intraday trading volume of 212.55K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.36%, 2.88%, and -23.12% respectively.
Institutional ownership of Artivion Inc. (NYSE: AORT) shares accounts for 89.70% of the company’s 40.12M shares outstanding. Mutual fund holders own 39.24%, while other institutional holders and individual stakeholders account for 49.16% and 17.71% respectively.
It has a market capitalization of $513.70M and a beta (3y monthly) value of 1.39. The earnings-per-share (ttm) stands at -$1.04. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.86% over the week and 4.58% over the month.
Analysts forecast that Artivion Inc. (AORT) will achieve an EPS of -$0.11 for the current quarter, -$0.08 for the next quarter and -$0.07 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.14 while analysts give the company a high EPS estimate of -$0.07. Comparatively, EPS for the current quarter was $0.26 a year ago. Earnings per share for the fiscal year are expected to increase by 13.60%, and 53.00% over the next financial year. EPS should grow at an annualized rate of 2.00% over the next five years, compared to -26.00% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Artivion Inc. (AORT) as a “Strong Buy” at a consensus score of 1.70. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 1 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the AORT, a number of firms have released research notes about the stock. Lake Street stated their Buy rating for the stock in a research note on September 27, 2022, with the firm’s price target at $32-$28. Lake Street coverage for the Artivion Inc. (AORT) stock in a research note released on August 08, 2022 offered a Buy rating with a price target of $32.